Dr. López de Munain is Chief Scientific Officer and Co-Founder of Miramoon
Pharma, with over 35 years of experience in clinical neurology, neurogenetics,
and translational neuroscience. He holds an MD and a PhD in Medicine from the
University of Navarra, where he conducted his doctoral research on myotonic
dystrophy. His scientific career has focused on the molecular and clinical bases of
neurogenetic disorders, with major contributions in neuromuscular and
neurodegenerative diseases including ALS, Parkinson’s disease, prion diseases,
and frontotemporal dementias. He has coordinated large national and
international research programs, led multicenter clinical trials, and established
research networks.
Dr. López de Munain is Principal Investigator of the Donostia group at the Center
for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
where he has served as Scientific Director since 2020. He is also member of the
Steering Committee of the Basque Biobank, the Board of the Matia Foundation,
and the Health and Quality of Life Division of TECNALIA.
He has authored over 350 peer-reviewed publications, 26 book chapters, and
more than 400 conference presentations (H-index 71), and has supervised 22
PhD theses. An active member of the Spanish Society of Neurology, he has
chaired its Basque regional branch and coordinated its study groups on
Neuromuscular Diseases and Neurogenetics.
Dr. López de Munain is also Associate Professor of Neurology at the University
of the Basque Country and the University of Deusto. He co-founded the Ilundain
Foundation, MIAKER Developments, and Athenea Neuroclinics, and in 2019
co-founded Miramoon Pharma to advance innovative therapies for central
nervous system and neuromuscular disorders. He received the 2022 Biomedical
Research Award from the Spanish Society of Neurology.
